● Recruiting

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Condition: Locally Advanced (Inoperable) or Metastatic Breast Cancer · Sponsor: AstraZeneca

PhasePhase 3

Planned participants895

Who can joinAll sexes, 18 Years to 99 Years

Healthy volunteersNo

About this study

A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

AstraZeneca Breast Cancer Study Locator Service · 1-877-400-4655 · az-bcsl@careboxhealth.com

Always discuss trial participation with your own doctor first.

Locations (284)

Research Site	Tucson, Arizona, United States	Recruiting
Research Site	Fountain Valley, California, United States	Recruiting
Research Site	Glendale, California, United States	Recruiting
Research Site	Los Angeles, California, United States	Recruiting
Research Site	Los Angeles, California, United States	Withdrawn
Research Site	Napa, California, United States	Recruiting
Research Site	Newport Beach, California, United States	Recruiting
Research Site	San Francisco, California, United States	Recruiting
Research Site	Santa Barbara, California, United States	Withdrawn
Research Site	Santa Rosa, California, United States	Recruiting
Research Site	Aurora, Colorado, United States	Recruiting
Research Site	New Haven, Connecticut, United States	Recruiting

+ 272 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04862663